Complex diseases affect us all. Illumina is committed to advancing our understanding of complex diseases and how they will be diagnosed and treated.
Complex diseases result from a combination of genetic and environmental factors, many of which are not understood. These diseases include neurodegenerative, psychiatric, and autoimmune disorders, and others.
The expanding Illumina complex disease product portfolio includes array and next-generation sequencing (NGS) technologies that are helping drive a revolution in complex disease genomics. These solutions deliver high-quality, reproducible results that accelerate research on various complex diseases. These discoveries have the potential to lead to life-changing improvements for patients and their loved ones.
This review gives a general overview of how genomic technologies and NGS can help in the study of complex diseases, and highlights recent publications featuring Illumina technology.Read Publication Review
Researchers perform large GWAS studies with the Global Screening Array to identify disease-associated DNA risk loci and develop PRSs for clinical validation.Read Interview
Illumina sequencing and software analysis are best in class for accuracyRead Article
A computer scientist transforms the world of biology by making bioinformatics tools available to all.Read Interview
New library prep kits enhance research in rare genetic diseasesRead Article
There are many genetic loci involved in cancer risk. Read more about how using NGS to understand the polygenicity of cancer can help researchers predict cancer risk and customize precision prevention.Learn More